Radiotherapy for metastatic esophageal cancer responding to immunotherapy
Treatments studied
Part of Cancer, Digestive system clinical trials.
This trial tests whether adding radiotherapy can help people with metastatic esophageal cancer that has already responded well to initial treatment with immunotherapy and chemotherapy. It may offer a way to improve outcomes for those whose cancer has not progressed after 2-4 cycles of first-line treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with metastatic squamous cell carcinoma of the esophagus that has spread to distant organs (stage IVb) or has recurred after prior treatment with surgery or radiation, as long as the recurrence is not in the previously radiated area.
- You have received 2-4 cycles of first-line chemotherapy combined with an immunotherapy drug (PD-1 inhibitor) and your cancer has responded (shrunk or stabilized) to that treatment.
- You are 18 years or older, and your overall health status is good (ECOG score 0 or 1). If you are 65 or older, you will need a special health assessment to confirm you are fit for the trial.
- You do not have any other active cancer (except for certain very low-risk types like non-malignant skin cancer or cervical carcinoma in situ).
- You have no active infection, serious heart or brain events in the past 6 months, or any condition that would make radiotherapy unsafe (like a high risk of fistula).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether adding radiation therapy to a standard treatment (immunotherapy plus chemotherapy) can help people with advanced esophageal cancer that has spread to up to two organs. The goal is to see if the combination improves outcomes.
This study tests whether giving radiation therapy based on how well the tumor responds to initial chemoimmunotherapy can improve outcomes for people with a certain type of esophageal cancer. The goal is to find a more personalized treatment approach that may be more effective and possibly reduce side effects.
This trial studies how to best target radiation for people with advanced esophageal cancer who are also getting immunotherapy. It aims to improve treatment planning to help patients live longer with fewer side effects.
This trial tests a treatment for locally advanced esophageal cancer. You'll receive chemoradiation (chemo plus radiation) followed by a maintenance drug (a PD-1 inhibitor) to help prevent the cancer from coming back.
This trial tests whether adding immunotherapy to standard chemoradiation can help people with unresectable locally advanced esophageal cancer. It aims to improve outcomes for those who cannot have surgery.
This trial tests if giving chemotherapy and radiation before surgery, followed by immunotherapy, can improve outcomes for people with a specific type of esophageal cancer that can be surgically removed.
Hear when a new Esophageal Neoplasm Metastatic trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.